StockData

AC Immune vs Praxis Precision Medicines

ACIU and PRAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACIU and PRAX compare

Praxis Precision Medicines scores higher on the StockData Score (7 against 3 for AC Immune), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACIUPRAX
Size and price
Market cap–$8.7B
Share price$2.09$310.27
Change, 1 year−35.3%74.2%
Change, 5 years−59.6%23.4%
Beta (5Y)0.221.90
Employees122168
StockData Score
Total score37 (better)
Valuation score00
Growth score00
Performance score01 (better)
Health score36 (better)
Dividend score00
Valuation
P/B–6.5×
FCF yield–−3.5%
Growth
Revenue growth (TTM)−86.9%–
Revenue growth, 5Y average−25.4%–
Profitability
Operating margin−1940%–
FCF margin−1964%–
Return on equity–−38.9%
Financial health
Debt / equity–0.00
Interest coverage−362.9×–
Current ratio0.9315.73 (better)
Altman Z-score–104.35
Piotroski F-score–3
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–121%
Held by insiders4.4%0.72%
Insider net buying, 12 months−$27.9K (better)−$3.6M
Short interest, % of float–15.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.